Last updated: September 2, 2026
Delafloxacin meglumine, marketed as Baxdela by Melinta Therapeutics, is a branded fluoroquinolone used for acute bacterial skin and skin-structure infections and community-acquired bacterial pneumonia. Its commercial value is constrained by a narrow hospital-focused market, intense competition from established generic antibiotics, fluoroquinolone safety concerns, and limited public disclosure of product-level revenue. The asset retains strategic value through intravenous-to-oral dosing, activity against methicillin-resistant Staphylococcus aureus (MRSA), and coverage of selected resistant Gram-positive and Gram-negative pathogens.
What is delafloxacin meglumine and how is Baxdela used?
Delafloxacin is a synthetic fluoroquinolone antibacterial. The marketed product contains delafloxacin meglumine and is available as an intravenous formulation and an oral tablet.
| Attribute |
Delafloxacin meglumine |
| Brand |
Baxdela |
| Active ingredient |
Delafloxacin |
| Developer |
Rib-X Pharmaceuticals, later Melinta Therapeutics |
| FDA approval |
June 19, 2017 |
| Initial indication |
Acute bacterial skin and skin-structure infections |
| Additional indication |
Community-acquired bacterial pneumonia |
| Dosage forms |
Intravenous infusion and oral tablets |
| Common adult dosing |
300 mg IV every 12 hours or 450 mg orally every 12 hours |
| Typical treatment duration |
Five to 14 days, depending on indication and clinical response |
| Drug class |
Fluoroquinolone antibacterial |
| Regulatory pathway |
New drug application |
| Primary commercial setting |
Hospital and infectious-disease treatment |
The FDA approved Baxdela in 2017 for acute bacterial skin and skin-structure infections caused by susceptible organisms, including MRSA. In 2019, the agency expanded the label to include community-acquired bacterial pneumonia in adults.[1,2]
The IV and oral formulations create a step-down treatment option for patients who begin therapy in the hospital and later transition to oral treatment. That feature can reduce reliance on continued intravenous access, although the economic benefit depends on formulary placement and hospital treatment protocols.
When did delafloxacin lose exclusivity?
Delafloxacin received new chemical entity exclusivity and Qualified Infectious Disease Product treatment under the Generating Antibiotic Incentives Now Act. The combined statutory exclusivity period was generally 10 years from approval, subject to the scope of FDA exclusivity protections and any applicable patent rights.[3]
| Milestone |
Date or period |
| FDA approval for skin infections |
June 19, 2017 |
| Five-year NCE exclusivity |
Generally through June 2022 |
| QIDP extension |
Five additional years |
| Approximate combined regulatory exclusivity |
Through June 2027 |
| CABP supplemental approval |
October 2019 |
| Patent and regulatory protection after 2027 |
Dependent on listed patents, pediatric exclusivity and litigation outcomes |
The 10-year period does not automatically prevent every form of generic competition before 2027. ANDA applicants may challenge listed patents through Paragraph IV certifications. Regulatory exclusivity, patent protection, formulation claims and litigation settlements must be assessed separately.
The QIDP framework was important commercially because delafloxacin entered a crowded antibacterial market with limited pricing power. The extended exclusivity period gave Melinta more time to build hospital contracts and infectious-disease adoption before generic entry.
What patents protect delafloxacin and Baxdela?
Delafloxacin is protected by a combination of compound, salt, formulation, dosage-form and method-of-use rights. The patent estate is more difficult to evaluate than the regulatory exclusivity timeline because ownership and Orange Book listing status have changed across transactions involving Rib-X, Melinta and related entities.
The relevant protection categories are:
Compound and chemical-entity patents
Early patents covering the delafloxacin molecule and related quinolone compounds were filed years before FDA approval. Their practical value depends on patent term adjustment, terminal disclaimers, continuations and the precise claim scope.
Delafloxacin meglumine salt protection
The commercial product uses a meglumine salt. Salt-form patents can protect crystallinity, stability, solubility or pharmaceutical processing characteristics, but their enforceability depends on claim construction and whether an ANDA product practices the claimed salt or manufacturing process.
IV formulation patents
IV delafloxacin requires a formulation suitable for reconstitution and infusion. Formulation claims may address excipient composition, pH, concentration, stability and preparation method. These claims can delay or complicate generic IV entry even when the underlying compound patent has expired.
Oral tablet patents
Oral tablet patents may cover dosage strength, solid-state properties, excipients, dissolution profile or manufacturing methods. A generic applicant can seek approval for a product that avoids particular formulation claims, but that strategy can create product-specific litigation risk.
Method-of-use patents
Method patents may cover treatment of acute bacterial skin and skin-structure infections, community-acquired bacterial pneumonia, or infections caused by specified susceptible pathogens. Their commercial impact depends on whether the FDA-approved label includes the patented indication and whether a generic applicant uses a section viii statement or omits the protected use.
Orange Book status
The FDA Orange Book is the controlling source for listed patents, patent-use codes and expiration information for approved small-molecule products.[4] Baxdela's commercial protection should therefore be analyzed through the current Orange Book entries rather than through historical patent-family summaries alone.
A precise patent-expiration table cannot be stated without a current Orange Book and Patent and Exclusivity Search review. The regulatory milestone that can be stated with confidence is the approximate June 2027 end of combined NCE and QIDP exclusivity.
What is the FDA regulatory status of Baxdela?
Baxdela is FDA-approved for two adult indications:
- Acute bacterial skin and skin-structure infections.
- Community-acquired bacterial pneumonia.
The FDA label includes warnings associated with systemic fluoroquinolones, including tendinitis and tendon rupture, peripheral neuropathy, central nervous system effects, exacerbation of myasthenia gravis, and potentially serious blood-glucose disturbances.[1] These class warnings affect prescribing behavior and can limit use when alternatives are available.
Delafloxacin's clinical positioning is strongest when physicians require:
- MRSA coverage;
- a single agent with both IV and oral forms;
- treatment of selected polymicrobial infections;
- an alternative for patients with limitations involving beta-lactams or other agents;
- hospital therapy that can transition to oral treatment without switching antibacterial class.
The drug is not a broad replacement for standard empiric hospital regimens. Stewardship committees commonly reserve newer antibiotics for resistant pathogens, treatment failure or selected patient profiles.
How does delafloxacin compare with competing antibiotics?
Delafloxacin competes against low-cost generic antibiotics and newer branded agents rather than against one direct substitute.
| Competitor |
Main strength |
Commercial pressure on Baxdela |
| Vancomycin |
Low cost and established MRSA use |
Strong inpatient price pressure |
| Linezolid |
Oral bioavailability and generic availability |
Competes in MRSA and oral step-down treatment |
| Ceftaroline |
Established MRSA indication |
Competes in hospital skin infections and pneumonia |
| Dalbavancin |
Long-acting IV dosing |
Reduces need for inpatient IV therapy |
| Oritavancin |
Single-dose or extended-dose IV treatment |
Competes in outpatient skin-infection management |
| Omadacycline |
Oral and IV tetracycline-class option |
Competes in skin infections and pneumonia |
| Lefamulin |
Community-acquired pneumonia positioning |
Competes in selected pneumonia patients |
| Generic fluoroquinolones |
Low price and familiarity |
Limits premium pricing and broad adoption |
Delafloxacin's differentiators are its MRSA activity, oral formulation, IV-to-oral continuity and activity against selected Gram-negative organisms. Its disadvantages include high competition, class safety concerns, limited clinical familiarity and the availability of inexpensive generic alternatives.
What are the market dynamics for delafloxacin?
Hospital formulary adoption
Baxdela depends heavily on hospital and integrated delivery network formulary decisions. The buying process evaluates acquisition price, antimicrobial stewardship, length of stay, IV-to-oral conversion, resistance patterns and infectious-disease specialist preference.
Hospital adoption is difficult for newer antibiotics because stewardship committees often restrict use. A drug may be listed on formulary but still generate limited volume if its use requires preauthorization or infectious-disease consultation.
Antimicrobial resistance
Resistance creates a clinical need for differentiated antibiotics, but it does not automatically create large commercial markets. Hospitals generally reserve newer agents for cases in which older antibiotics are unsuitable. That limits volume while increasing the importance of targeted reimbursement and clinical evidence.
IV-to-oral economics
The oral tablet gives Baxdela a potential economic advantage over therapies requiring prolonged IV administration. The benefit can include fewer line complications, lower infusion costs and earlier discharge. In practice, the value is realized only when hospitals permit oral step-down use and payers reimburse the oral product at a commercially sustainable level.
Fluoroquinolone class risk
Fluoroquinolone warnings restrict use in situations where safer alternatives are effective. Some clinicians avoid the class for non-severe infections, uncomplicated conditions or patients with elevated risk of tendon, neurologic or cardiovascular adverse events.
Generic price erosion
Once generic delafloxacin becomes available, the product is likely to face price erosion in both oral and IV channels. The speed of erosion will depend on the number of approved ANDAs, the scope of remaining patents, manufacturing complexity and whether generic entrants launch at risk.
What is the financial trajectory of delafloxacin?
Public product-level financial disclosure for Baxdela is limited because Melinta is privately held. The company has not consistently reported Baxdela revenue as a standalone line item in public-company filings. That prevents a reliable year-by-year revenue series comparable with products marketed by publicly traded pharmaceutical companies.
The financial trajectory can be divided into four phases.
2017 to 2018: launch and market access buildout
Baxdela launched after FDA approval in 2017. Early investment focused on sales infrastructure, hospital formulary access, physician education and payer coverage. The product entered a market where clinical differentiation was meaningful but price competition from generic antibiotics was severe.
2019 to 2020: indication expansion and portfolio consolidation
The 2019 CABP approval increased the addressable market beyond skin infections.[2] The expansion also strengthened the asset's strategic value within Melinta's hospital anti-infective portfolio.
Melinta later acquired Tetraphase Pharmaceuticals, adding Xerava to its antibacterial portfolio. The transaction increased commercial scale and allowed the company to market multiple hospital antibiotics, but it also created integration and portfolio-management demands.[5]
2021 to 2023: portfolio commercialization
Melinta's commercial model centered on hospital anti-infectives, including Baxdela, Vabomere, Orbactiv and Xerava. Portfolio selling can lower commercial costs per product and improve contracting leverage. It can also lead hospitals to evaluate products collectively rather than on the clinical merits of one antibiotic.
No audited, publicly reported Baxdela revenue trajectory is available for this period. Any precise annual-sales estimate should therefore be treated as a third-party estimate rather than a company-reported figure.
2024 to 2027: protection harvest and generic preparation
The principal commercial question is whether Melinta can increase adoption before the end of the combined regulatory exclusivity period and preserve value through patent protection, contracting, lifecycle management or a generic settlement.
Potential value levers include:
- broader hospital formulary placement;
- increased IV-to-oral conversion;
- improved use in resistant infections;
- additional real-world evidence;
- improved payer coverage;
- co-promotion or licensing;
- pediatric or label-based exclusivity opportunities;
- manufacturing efficiencies.
The central downside is that market expansion may remain insufficient to offset the cost of commercial infrastructure and hospital access. Delafloxacin can remain clinically relevant while producing modest revenue relative to larger anti-infective products.
Which companies are challenging Baxdela with generics?
Potential generic competitors would typically file ANDAs with paragraph certifications addressing listed patents. The FDA may approve a generic before commercial launch if statutory exclusivity has expired and the applicant has satisfied patent requirements, but launch timing can be delayed by litigation, settlement terms or remaining claims.
No reliable public basis supports identifying a specific current Paragraph IV challenger without a current FDA Orange Book review, FDA litigation records and federal court docket analysis. The relevant competitive risk is structural:
- oral tablets are likely to attract generic interest because of manufacturing scale and outpatient distribution;
- IV products may face fewer entrants if formulation, sterile manufacturing or demand economics are less attractive;
- a first generic entrant could capture substantial share through hospital contracting;
- multiple entrants would accelerate price erosion;
- an at-risk launch could trigger damages exposure if a listed patent is later upheld.
What patent litigation affects delafloxacin?
Patent litigation risk centers on ANDA challenges to listed patents and possible disputes over compound, salt, formulation or method-of-use claims. The litigation economics are shaped by the limited size of the branded market.
For a relatively small hospital product, a patent holder may prefer settlement or licensing over extended litigation if the expected legal cost is high relative to recoverable damages. A settlement could establish a delayed generic-entry date, but its terms would require review under the applicable antitrust and FDA settlement-disclosure framework.
The absence of widely reported high-value litigation does not establish that the estate is weak. It may reflect limited generic incentive, confidential negotiations, insufficient market size or the timing of future ANDA filings.
How strong is the delafloxacin patent estate?
The estate appears commercially useful but not comparable to the patent protection surrounding a blockbuster medicine.
Its strengths are:
- extended regulatory exclusivity through the QIDP framework;
- multiple potential protection layers;
- differentiated IV and oral dosage forms;
- clinical relevance in MRSA and selected resistant infections;
- possible manufacturing and formulation barriers.
Its weaknesses are:
- mature underlying fluoroquinolone technology;
- likely historical patent expirations before or near the end of regulatory exclusivity;
- limited market size;
- strong substitution from generic therapies;
- potential design-around options for formulation and method claims;
- substantial class-level safety warnings.
The most important protection question is whether a generic applicant can obtain approval and launch an equivalent product after June 2027 without infringing enforceable listed claims. Regulatory exclusivity alone is unlikely to support durable post-2027 pricing.
What generic launch scenarios exist for Baxdela?
| Scenario |
Timing |
Market effect |
| No ANDA challenge before regulatory exclusivity ends |
Around or after June 2027 |
Gradual generic entry, depending on patent status |
| Paragraph IV challenge with successful settlement |
Settlement-defined date |
Predictable delayed entry and possible licensing economics |
| Patent litigation with branded win |
After litigation |
Delayed entry and continued branded protection |
| Patent litigation with generic win |
Potentially before all patent expirations |
Rapid share loss and price reduction |
| Single generic entrant |
First approved commercial entrant |
Moderate initial erosion, stronger contracting pressure |
| Multiple generic entrants |
After additional approvals |
Faster price erosion and reduced branded volume |
| Authorized generic or license |
Company-controlled timing |
May preserve channel access but reduce net price |
The oral product is more likely to experience rapid substitution because retail and specialty-pharmacy distribution can support generic dispensing. IV substitution may be slower if hospitals require formulary review, sterile supply reliability and procurement qualification.
What licensing deals and ownership changes affect commercial value?
Delafloxacin originated at Rib-X Pharmaceuticals and was commercialized by Melinta. Ownership and portfolio transactions are material because they affect sales resources, manufacturing agreements, contracting strategy and the probability of lifecycle investment.
Melinta's acquisition of Tetraphase Pharmaceuticals added Xerava and expanded the company's hospital anti-infective portfolio.[5] A broader portfolio can improve access to hospital buyers, but it does not guarantee higher Baxdela revenue. Publicly available information does not establish a major standalone out-license of Baxdela that would provide a dependable royalty forecast.
For valuation, analysts should distinguish:
- product revenue;
- gross-to-net deductions;
- hospital purchasing discounts;
- co-promotion payments;
- manufacturing cost;
- sales and marketing expense;
- milestone or royalty obligations;
- debt or preferred-equity claims at the company level.
What revenue exposure does delafloxacin create for Melinta?
Baxdela is strategically important but unlikely to be the sole determinant of Melinta's enterprise value. The company operates a portfolio of hospital anti-infectives, so revenue exposure is distributed across multiple products.
Baxdela's financial contribution is exposed to:
- formulary restrictions;
- hospital budget pressure;
- generic substitution;
- fluoroquinolone safety perceptions;
- antimicrobial-resistance trends;
- payer reimbursement;
- inventory and supply reliability;
- timing of ANDA filings;
- sales-force productivity.
Because Baxdela revenue is not separately disclosed in a consistent public reporting series, product-specific valuation requires modeled assumptions rather than reported financial statements. The most defensible approach is scenario analysis based on hospital penetration, treated patient volume, net price, oral-versus-IV mix and generic-entry timing.
What geographic markets are relevant to delafloxacin?
The United States is the primary market because FDA approval and the QIDP framework provide the clearest regulatory and exclusivity platform. International opportunity is more limited by local regulatory approvals, reimbursement and the availability of generic fluoroquinolones.
Geographic commercial barriers include:
- separate marketing authorization requirements;
- national hospital formularies;
- antimicrobial stewardship policies;
- local reference pricing;
- tender-based procurement;
- country-specific patent terms;
- local manufacturing or distribution requirements.
A U.S. generic launch would not automatically create equivalent competition in Europe or other regions. Conversely, weak international uptake would reduce the value of global licensing opportunities.
What manufacturing and intellectual-property barriers affect generic entry?
Delafloxacin's oral form is comparatively accessible to generic manufacturers if the active pharmaceutical ingredient and formulation process can be reproduced economically. The IV product presents greater operational requirements because sterile manufacturing, stability, reconstitution and supply reliability are important to hospital buyers.
Potential barriers include:
- access to qualified delafloxacin API;
- salt-form control;
- solid-state and dissolution performance;
- sterile fill-finish capacity;
- stability data;
- bioequivalence requirements;
- formulation patent claims;
- hospital procurement qualification.
These barriers may limit the number of generic entrants, but they are unlikely to eliminate generic competition once the commercial opportunity becomes large enough.
How does delafloxacin compare with other newer hospital antibiotics?
Delafloxacin has a broader practical use case than a single-indication product because it is approved for both skin infections and community-acquired bacterial pneumonia. Its IV-to-oral profile is also commercially useful.
Its main disadvantage is that the underlying fluoroquinolone class is heavily genericized. Newer agents such as ceftobiprole, cefiderocol, omadacycline and lefamulin may command more specialized clinical niches, while dalbavancin and oritavancin compete through long-acting dosing. Delafloxacin sits between low-cost generics and highly specialized reserve antibiotics.
Key Takeaways
- Delafloxacin meglumine is marketed in the United States as Baxdela by Melinta Therapeutics.
- FDA approval began in 2017 for acute bacterial skin and skin-structure infections, followed by a 2019 community-acquired bacterial pneumonia indication.
- Combined NCE and QIDP exclusivity generally points to June 2027 as the key regulatory-loss-of-exclusivity date.
- The commercial product benefits from MRSA activity and IV-to-oral dosing.
- Generic vancomycin, linezolid and other low-cost agents impose substantial pricing pressure.
- Product-level Baxdela revenue is not consistently disclosed publicly, limiting precise financial modeling.
- Oral generic entry is likely to create faster substitution than IV entry.
- The patent estate should be assessed through current FDA Orange Book listings, patent-family review and ANDA litigation records.
- Long-term value depends more on hospital adoption and generic-entry timing than on broad population growth.
FAQs About Delafloxacin Meglumine
Is delafloxacin meglumine the same as Baxdela?
Yes. Baxdela is the branded product containing delafloxacin meglumine, the salt form used in the approved oral and intravenous products.
Is delafloxacin a biologic or a small-molecule drug?
Delafloxacin is a small-molecule fluoroquinolone antibacterial. It is subject to the ANDA generic pathway rather than the biosimilar pathway.
Does delafloxacin have biosimilar risk?
No. Biosimilars apply to biologic products. Delafloxacin faces generic-drug risk through ANDA filings and patent challenges.
Can delafloxacin be used for community-acquired pneumonia?
Yes. FDA approved Baxdela for community-acquired bacterial pneumonia in adults in 2019.[2]
What is the main investment risk for Baxdela?
The main risk is limited commercial scale before generic competition, combined with hospital formulary restrictions, fluoroquinolone safety concerns and price pressure from established generic antibiotics.
References
-
U.S. Food and Drug Administration. (2023). Baxdela (delafloxacin meglumine) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2019). FDA approves new fluoroquinolone antibacterial for community-acquired bacterial pneumonia. FDA.
-
U.S. Congress. (2012). Food and Drug Administration Safety and Innovation Act, Title VIII: Generating Antibiotic Incentives Now Act. 21 U.S.C. § 355f.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
Tetraphase Pharmaceuticals, Inc. (2020). Tetraphase Pharmaceuticals announces stockholder approval of merger with Melinta Therapeutics. Company press release.
